Chemoimmunotherapy of melanoma. Is it time for phase III trials?
Cancer
.
1995 Feb 15;75(4):905-7.
doi: 10.1002/1097-0142(19950215)75:4<905::aid-cncr2820750402>3.0.co;2-a.
Author
U Keilholz
PMID:
7842409
DOI:
10.1002/1097-0142(19950215)75:4<905::aid-cncr2820750402>3.0.co;2-a
No abstract available
Publication types
Comment
Editorial
MeSH terms
Clinical Trials, Phase III as Topic
Combined Modality Therapy
Dacarbazine / therapeutic use*
Humans
Immunotherapy
Interleukin-2 / therapeutic use*
Melanoma / therapy*
Substances
Interleukin-2
Dacarbazine